Clinical Trial Update: Neutrophil Gelatinase-associated Lipocalin (NGAL) Evaluation in Emergency Department (ED) All-Comers

View source ↗

Summary

A completed trial evaluating NGAL as a biomarker for acute kidney injury in emergency department all-comers. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Snippet

Sponsor: Abbott RDx Cardiometabolic | Conditions: Acute Kidney Injury | Status: COMPLETED